Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.

Pavlakovic H, Becker J, Albuquerque R, Wilting J, Ambati J.

Ann N Y Acad Sci. 2010 Oct;1207 Suppl 1:E7-15. doi: 10.1111/j.1749-6632.2010.05714.x.

2.

Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Becker J, Pavlakovic H, Ludewig F, Wilting F, Weich HA, Albuquerque R, Ambati J, Wilting J.

Clin Cancer Res. 2010 Mar 1;16(5):1431-41. doi: 10.1158/1078-0432.CCR-09-1936. Epub 2010 Feb 23.

3.

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, Baffi JZ, Yamada K, Kaneko H, Green MG, Chappell J, Wilting J, Weich HA, Yamagami S, Amano S, Mizuki N, Alexander JS, Peterson ML, Brekken RA, Hirashima M, Capoor S, Usui T, Ambati BK, Ambati J.

Nat Med. 2009 Sep;15(9):1023-30. doi: 10.1038/nm.2018. Epub 2009 Aug 9.

4.

Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity.

Singh N, Tiem M, Watkins R, Cho YK, Wang Y, Olsen T, Uehara H, Mamalis C, Luo L, Oakey Z, Ambati BK.

Blood. 2013 May 16;121(20):4242-9. doi: 10.1182/blood-2012-08-453043. Epub 2013 Mar 8.

5.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.

Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.

6.

Sunitinib inhibits inflammatory corneal lymphangiogenesis.

Detry B, Blacher S, Erpicum C, Paupert J, Maertens L, Maillard C, Munaut C, Sounni NE, Lambert V, Foidart JM, Rakic JM, Cataldo D, Noël A.

Invest Ophthalmol Vis Sci. 2013 May 3;54(5):3082-93. doi: 10.1167/iovs.12-10856.

PMID:
23580490
7.

Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.

Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS.

Cancer Res. 2008 Jan 15;68(2):521-9. doi: 10.1158/0008-5472.CAN-07-3217.

8.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.

Breast Cancer Res. 2011 Jun 21;13(3):R66. doi: 10.1186/bcr2903.

9.

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M, Alitalo K.

J Exp Med. 2007 Jun 11;204(6):1431-40. Epub 2007 May 29.

10.

Molecular control of lymphatic metastasis.

Achen MG, Stacker SA.

Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Review.

PMID:
18519975
11.

VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.

Oh SJ, Jeltsch MM, Birkenhäger R, McCarthy JE, Weich HA, Christ B, Alitalo K, Wilting J.

Dev Biol. 1997 Aug 1;188(1):96-109.

12.

Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.

Kaza E, Ablasser K, Poutias D, Griffiths ER, Saad FA, Hofstaetter JG, del Nido PJ, Friehs I.

Cardiovasc Res. 2011 Feb 1;89(2):410-8. doi: 10.1093/cvr/cvq321. Epub 2010 Oct 8.

13.

Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.

Kubo H, Cao R, Brakenhielm E, Mäkinen T, Cao Y, Alitalo K.

Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8868-73. Epub 2002 Jun 17.

14.

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K.

J Natl Cancer Inst. 2002 Jun 5;94(11):819-25.

15.

Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.

Lohela M, Heloterä H, Haiko P, Dumont DJ, Alitalo K.

Am J Pathol. 2008 Dec;173(6):1891-901. doi: 10.2353/ajpath.2008.080378. Epub 2008 Nov 6.

16.

Differential expression of VEGF ligands and receptors in prostate cancer.

Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED.

Prostate. 2013 May;73(6):563-72. doi: 10.1002/pros.22596. Epub 2012 Oct 4.

PMID:
23038639
17.
18.

Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.

Karpanen T, Wirzenius M, Mäkinen T, Veikkola T, Haisma HJ, Achen MG, Stacker SA, Pytowski B, Ylä-Herttuala S, Alitalo K.

Am J Pathol. 2006 Aug;169(2):708-18.

19.

A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.

Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS.

Mol Cancer Res. 2004 Jun;2(6):315-26.

20.

Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.

Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, Dana R.

Am J Pathol. 2009 Nov;175(5):1984-92. doi: 10.2353/ajpath.2009.080515. Epub 2009 Oct 1.

Items per page

Supplemental Content

Write to the Help Desk